R
RenovoRx
Medical device company headquartered in Silicon Valley, California
About RenovoRx
RenovoRx is a medical technology company specializing in innovative solutions for targeted cancer treatment. The company operates primarily in the healthcare sector, focusing on the development and commercialization of advanced medical devices for the delivery of chemotherapy. RenovoRx's flagship product, RenovoCath, is a dual balloon infusion catheter designed to deliver chemotherapy directly to the tumor site, enhancing treatment efficacy and minimizing systemic side effects.
Read full description
RenovoRx serves patients suffering from pancreatic and bile duct cancers, two of the most challenging and deadly forms of cancer. The company is actively involved in clinical trials, including the Phase III TIGeR PaC trial, to validate the effectiveness of its targeted delivery system.
The business model of RenovoRx revolves around the development, patenting, and commercialization of its medical devices. Revenue is generated through the sale of these devices to healthcare providers and institutions involved in cancer treatment. Additionally, the company may receive funding and grants for its research and development efforts.
RenovoRx operates in the U.S. and European markets, where it continues to expand its clinical trials and seek regulatory approvals. The company aims to address the unmet needs in cancer treatment by providing more effective and targeted therapeutic options.
At a glance
- Status
- Operational
- Founded
- 2009
- Headquarters
- San Jose, United States
- Listing
- IPO 2021
- Employees
- 30
- Open positions
- 2
- Dealroom signal
- 86.6/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Spinout, Biotech and Pharma, Woman Founder, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning RenovoRx.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| PRIVATE PLACEMENT NON VC✓Other financing | Mar 2026 | $10M | — | Undisclosed | ↗ |
| POST IPO EQUITY✓Other financing | Feb 2025 | $12M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for RenovoRx is 5.3K monthly website visits, down 1.9% over the last three months. RenovoRx's team grew 25% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Sand Hill Angels
Golden Seeds
The Angels' Forum
Plug and Play
Series B and later4 investors entered at this stage
- PNPneumRx
b2venture
Astia
Boston Scientific
Other known investors6 additional known investors
Stanford University
Joyo Wijaya
SeedFolio
Sharon Vosmek
StartX
SV Tech Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about RenovoRx on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See RenovoRx’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.